CN116514950A - 一种重组猪α-干扰素的制备方法 - Google Patents
一种重组猪α-干扰素的制备方法 Download PDFInfo
- Publication number
- CN116514950A CN116514950A CN202210798787.5A CN202210798787A CN116514950A CN 116514950 A CN116514950 A CN 116514950A CN 202210798787 A CN202210798787 A CN 202210798787A CN 116514950 A CN116514950 A CN 116514950A
- Authority
- CN
- China
- Prior art keywords
- alpha
- recombinant
- interferon
- poifn
- pichia pastoris
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 13
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 30
- 239000000047 product Substances 0.000 claims abstract description 21
- 238000000034 method Methods 0.000 claims abstract description 20
- 238000000855 fermentation Methods 0.000 claims abstract description 17
- 230000004151 fermentation Effects 0.000 claims abstract description 17
- 239000006228 supernatant Substances 0.000 claims abstract description 11
- 239000013604 expression vector Substances 0.000 claims abstract description 8
- 241000235342 Saccharomycetes Species 0.000 claims abstract description 6
- 238000010276 construction Methods 0.000 claims abstract description 4
- 238000000605 extraction Methods 0.000 claims abstract description 4
- 230000006698 induction Effects 0.000 claims abstract description 4
- 108010047761 Interferon-alpha Proteins 0.000 claims description 39
- 210000004027 cell Anatomy 0.000 claims description 38
- 102000006992 Interferon-alpha Human genes 0.000 claims description 35
- 239000013612 plasmid Substances 0.000 claims description 34
- 241000235058 Komagataella pastoris Species 0.000 claims description 32
- 239000007788 liquid Substances 0.000 claims description 18
- 238000012258 culturing Methods 0.000 claims description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 13
- 230000001580 bacterial effect Effects 0.000 claims description 11
- 239000001963 growth medium Substances 0.000 claims description 11
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 claims description 8
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 claims description 8
- 108010084455 Zeocin Proteins 0.000 claims description 8
- CWCMIVBLVUHDHK-ZSNHEYEWSA-N phleomycin D1 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC[C@@H](N=1)C=1SC=C(N=1)C(=O)NCCCCNC(N)=N)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C CWCMIVBLVUHDHK-ZSNHEYEWSA-N 0.000 claims description 8
- 238000001976 enzyme digestion Methods 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 6
- 230000009466 transformation Effects 0.000 claims description 6
- 241000588724 Escherichia coli Species 0.000 claims description 5
- 239000002609 medium Substances 0.000 claims description 5
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 4
- 239000005457 ice water Substances 0.000 claims description 4
- 230000001939 inductive effect Effects 0.000 claims description 4
- 238000009630 liquid culture Methods 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 4
- 230000035939 shock Effects 0.000 claims description 4
- 239000000600 sorbitol Substances 0.000 claims description 4
- 239000013598 vector Substances 0.000 claims description 4
- 241000235648 Pichia Species 0.000 claims description 3
- 239000002244 precipitate Substances 0.000 claims description 3
- 238000004321 preservation Methods 0.000 claims description 3
- 230000001502 supplementing effect Effects 0.000 claims description 3
- 108020004705 Codon Proteins 0.000 claims description 2
- 238000011084 recovery Methods 0.000 claims description 2
- 239000007787 solid Substances 0.000 claims description 2
- 238000003860 storage Methods 0.000 claims description 2
- 230000002194 synthesizing effect Effects 0.000 claims description 2
- 210000005253 yeast cell Anatomy 0.000 claims description 2
- 238000012216 screening Methods 0.000 claims 1
- 102000014150 Interferons Human genes 0.000 abstract description 19
- 108010050904 Interferons Proteins 0.000 abstract description 19
- 229940079322 interferon Drugs 0.000 abstract description 19
- 102000004169 proteins and genes Human genes 0.000 abstract description 14
- 240000004808 Saccharomyces cerevisiae Species 0.000 abstract description 8
- 238000000926 separation method Methods 0.000 abstract description 3
- 239000012535 impurity Substances 0.000 abstract description 2
- 230000008569 process Effects 0.000 abstract description 2
- 238000000746 purification Methods 0.000 abstract description 2
- 238000004153 renaturation Methods 0.000 abstract description 2
- 238000011031 large-scale manufacturing process Methods 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 20
- 238000003776 cleavage reaction Methods 0.000 description 14
- 230000007017 scission Effects 0.000 description 13
- 238000001962 electrophoresis Methods 0.000 description 12
- 230000000840 anti-viral effect Effects 0.000 description 9
- 239000000499 gel Substances 0.000 description 9
- 241000700605 Viruses Species 0.000 description 8
- 230000003115 biocidal effect Effects 0.000 description 8
- 238000004113 cell culture Methods 0.000 description 8
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 8
- 238000010790 dilution Methods 0.000 description 6
- 239000012895 dilution Substances 0.000 description 6
- 231100000645 Reed–Muench method Toxicity 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 4
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 4
- ROOXNKNUYICQNP-UHFFFAOYSA-N ammonium persulfate Chemical compound [NH4+].[NH4+].[O-]S(=O)(=O)OOS([O-])(=O)=O ROOXNKNUYICQNP-UHFFFAOYSA-N 0.000 description 4
- 244000309466 calf Species 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 230000000120 cytopathologic effect Effects 0.000 description 4
- 239000003147 molecular marker Substances 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 238000012408 PCR amplification Methods 0.000 description 3
- 239000007983 Tris buffer Substances 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 238000007664 blowing Methods 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 238000004043 dyeing Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000007365 immunoregulation Effects 0.000 description 3
- 239000011259 mixed solution Substances 0.000 description 3
- 239000012146 running buffer Substances 0.000 description 3
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- 108700010070 Codon Usage Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 102000012410 DNA Ligases Human genes 0.000 description 2
- 108010061982 DNA Ligases Proteins 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 108010019160 Pancreatin Proteins 0.000 description 2
- 229960000583 acetic acid Drugs 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 229910001870 ammonium persulfate Inorganic materials 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000002155 anti-virotic effect Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 238000004925 denaturation Methods 0.000 description 2
- 230000036425 denaturation Effects 0.000 description 2
- 239000012154 double-distilled water Substances 0.000 description 2
- 239000012362 glacial acetic acid Substances 0.000 description 2
- 230000004957 immunoregulator effect Effects 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 210000000822 natural killer cell Anatomy 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 229940055695 pancreatin Drugs 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 230000003248 secreting effect Effects 0.000 description 2
- 239000002356 single layer Substances 0.000 description 2
- 239000008223 sterile water Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- 244000153158 Ammi visnaga Species 0.000 description 1
- 235000010585 Ammi visnaga Nutrition 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 102000001617 Interferon Receptors Human genes 0.000 description 1
- 108010054267 Interferon Receptors Proteins 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 101150087698 alpha gene Proteins 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000000729 antidote Substances 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 238000003287 bathing Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000013553 cell monolayer Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 238000004042 decolorization Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 102000006240 membrane receptors Human genes 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- ZIUHHBKFKCYYJD-UHFFFAOYSA-N n,n'-methylenebisacrylamide Chemical compound C=CC(=O)NCNC(=O)C=C ZIUHHBKFKCYYJD-UHFFFAOYSA-N 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000012192 staining solution Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 239000007222 ypd medium Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/56—IFN-alpha
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/66—General methods for inserting a gene into a vector to form a recombinant vector using cleavage and ligation; Use of non-functional linkers or adaptors, e.g. linkers containing the sequence for a restriction endonuclease
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
- C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
- C12N15/815—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts for yeasts other than Saccharomyces
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/102—Plasmid DNA for yeast
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Mycology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
本发明提供一种重组猪α‑干扰素的制备方法,重组猪α‑干扰素的制备方法包括猪α‑干扰素真核表达载体的构建、重组酵母菌的诱导表达、发酵工艺和后续提取工艺。本发明具有培养成本低、产量高以及便于产物分离纯化等优点,通过酵母表达的α‑干扰素直接以有活性的干扰素的形式分泌在发酵液的上清液中,无需复杂的变复性等后续处理工艺,并且发酵液上清中杂蛋白含量低,易进行大规模的生产。
Description
技术领域
本发明涉及干扰素技术领域,尤其是一种重组猪α-干扰素的制备方法。
背景技术
干扰素(IFN)是一种广谱抗病毒剂,并不直接杀伤或抑制病毒,而主要是通过细胞表面受体作用使细胞产生抗病毒蛋白,从而抑制乙肝病毒的复制,其类型分为三类,α-(白细胞)型、β-(成纤维细胞)型,γ-(淋巴细胞)型;同时还可增强自然杀伤细胞(NK细胞)、巨噬细胞和T淋巴细胞的活力,从而起到免疫调节作用,并增强抗病毒能力。
干扰素是一组具有多种功能的活性蛋白质(主要是糖蛋白),是一种由单核细胞和淋巴细胞产生的细胞因子。它们在同种细胞上具有广谱的抗病毒、影响细胞生长,以及分化、调节免疫功能等多种生物活性。α-干扰素具有抗病毒、抗肿瘤和免疫调节作用,α-干扰素的免疫调节作用很强,还有增强免疫对病毒感染细胞的免疫杀伤活性,α-干扰素还能增强巨噬细胞的吞噬功能和细胞毒活性。
猪α-干扰素(poIFN-α)是一类具有抗病毒和免疫调节活性的细胞因子,是猪体抵御病原入侵的重要早期防御系统之一。应用基因工程的方法表达重组猪干扰素具有与天然干扰素高度相似的抗病毒等生物学活性,因此重组猪干扰素可以作为一类高效的抗病毒和免疫调节生物制剂。其作用机制表现为:病毒感染细胞导致IFN的产生,并随被感染细胞死亡、崩解而释出,IFN分子向附近扩散,随血液循环至全身。IFN是由宿主细胞编码的蛋白质,因其是通过作用于靶细胞、激活靶细胞内的基因而发挥作用的,故其具有广谱抗病毒作用。当IFN进入细胞后干扰素与细胞表面的干扰素受体结合后,可诱导细胞产生具有酶活性的抗病毒蛋白。
发明内容
针对现有技术的不足,本发明提供一种重组猪α-干扰素的制备方法,本发明通过将重组猪α-干扰素通过表达载体导入毕赤酵母菌株中,再通过重组毕赤酵母的诱导表达获得高产量重组蛋白。
本发明的技术方案为:一种重组猪α-干扰素的制备方法,所述的方法通过将猪α-干扰素基因通过表达载体导入毕赤酵母菌株,再通过毕赤酵母菌株的诱导表达、发酵和后提取制得。
作为优选的,所述的制备方法包括猪α-干扰素真核表达载体的构建、重组酵母菌的诱导表达,包括以下步骤:
S1)、利用毕赤酵母密码子的偏爱性优化猪α-干扰素poIFN-α基因序列,并将合成的基因构建入pGAPZαA载体中,人工合成含有目的基因的重组质粒pGAPZαA-poIFN-α;
S2)、通过毕赤酵母感受态的制备,电转重组质粒,将合成的质粒pGAPZαA-poIFN-α导入毕赤酵母中进行种子液的制备,以及摇瓶发酵诱导重组蛋白的表达。
作为优选的,所述的重组质粒pGAPZαA-poIFN-α的构建方法的步骤:
将目的基因poIFN-α和载体pGAPZαA分别进行双酶切,酶切位点是NotⅠ、XhoⅠ,然后将酶切回收产物poIFN-α和pGAPZαA进行连接,并将连接产物导入大肠杆菌Top10F’感受态细胞中,然后利用试剂盒提取获得重组质粒pGAPZαA-poIFN-α。对重组质粒进行线性化并纯化后电击转化至毕赤酵母X33感受态细胞中。
作为优选的,将通过电转导入毕赤酵母感受态的重组毕赤酵母菌液涂布在YPDS+Zeocin的低抗性平板上,并进行多次的高抗性筛选。
作为优选的,所述重组毕赤酵母菌株的诱导表达采用如下步骤:将筛选的重组酵母菌划线接种到YPDS+Zeocin的抗性平板上,30℃培养,挑取单菌落接种至YPD液体培养基中,30℃摇床培养16h,得到种子液;然后将种子液按比例接种至YPD液体培养基中,30℃开始诱导表达,每隔24小时,取发酵液保存,并补充等量的培养基,保存的发酵液中含有重组毕赤酵母菌株分泌表达的重组猪α-干扰素,取发酵液检测重组蛋白的表达情况。
作为优选的,上述中,每隔24小时,取1mL发酵液保存,并补充1mL的培养基,连续培养发酵96小时。
本发明的有益效果为:
1、本发明将猪α-干扰素poIFN-α基因克隆到毕赤酵母分泌性表达载体pGAPZαA使之整合到毕赤酵母染色体中,实现了poIFN-α重组蛋白在毕赤酵母中的分泌表达,并通过控制培养条件,使poIFN-α重组蛋白在毕赤酵母中大量分泌具有抗病毒活性的重组猪α-干扰素;
2、本发明毕赤酵母是一种能高效表达重组蛋白的酵母品种,具有完整的蛋白表达、加工和修饰功能,与杆状病毒、哺乳动物细胞相比,具有生长速度快、培养成本低、产量高及便于产物分离纯化等优点,通过酵母表达直接以有活性的干扰素形式分泌到发酵上清液中,较原核生物相比,真核系统操作简单,无复杂变性、复性等后续工艺,且发酵上清液中杂蛋白含量较低,非常适合进行大规模的工业化生产。
附图说明
图1为本发明猪α-干扰素PCR扩增的结果,图1中泳道M为DNA Maker DL2000,泳道poIFN-α为猪α-干扰素PCR扩增的条带;
图2为本发明pGAPZαA质粒和pGAPZαA-poIFN-α分别用NotⅠ、XhoⅠ单双酶切的结果,其中,图2中,将菌液PCR鉴定为阳性的菌株扩培提取的质粒(编号为1号质粒和2号质粒),用NotⅠ、XhoⅠ单双酶切,泳道M为DNA Maker DL2000,泳道1-4为分别为1号质粒、NotⅠ单酶切、XhoⅠ单酶切、NotⅠ和XhoⅠ双酶切的条带;泳道5-8为2号质粒、NotⅠ单酶切、XhoⅠ单酶切、NotⅠ和XhoⅠ双酶切的条带;
图3为本发明毕赤酵母系统重组猪α-干扰素X33-51菌株的SDS-PAGE电泳检测结果;图3中泳道M为蛋白低分子Maker 40kD,泳道1-4是pGAPZαA-PoIFN-α的X33-51菌株24h/48h/72h/96h酵母表达产物;
图4为本发明毕赤酵母系统重组猪α-干扰素X33-29菌株的SDS-PAGE电泳检测结果;其中,图4中泳道M为蛋白低分子Maker 40kD,泳道5-8是pGAPZαA-PoIFN-α的X33-29菌株24h/48h/72h/96h酵母表达产物。
具体实施方式
下面结合附图对本发明的具体实施方式作进一步说明:
实施例1
本实施例提供重组猪α干扰素的构建
1、基于毕赤酵母密码子偏好性优化猪的α干扰素表达基因编码序列,根据毕赤酵母(Pichia pastoris)密码子偏好性和GC含量使用生物软件DNA Works进行优化猪α干扰素基因序列,优化后的基因序列委托江苏金斯瑞生物科技公司合成。
优化后的poIFN-α序列如SEQ ID NO.1所示:
TGTGATCTACCTCAGACTCATAGTCTTGCTCACACTAGAGCCCTGAGATTGCTTGCTCAAATGAGAAGAATCTCACCATTCTCATGTTTGGATCATCGTCGTGACTTTGGAAGTCCACATGAAGCTTTGGGTGGTAACCAGGTTCAAAAGGCACAGGCCATGGCATTGGTTCACGAAATGTTGCAACAGACTTTTCAACTATTCTCTACTGAGGGATCAGCAGCCGCCTGGGACGAGTCATTGTTGCATCAATTCTGCACCGGATTGGATCAACAATTACGAGATTTGGAAGCTTGTGTCATGCAAGAAGTCGGCTTGGAAGGTACTCCACTTTTGGAAGAGGACAGTATTCTAGCCGTTAGAAAGTATTTCCATAGGCTACCCTTGTACCTACAAGAAAAATCCTATAGTCCATGTGCTTGGGAAATTGTGCGTGCTGAAGTTATGAGGGTGTTTTCTTCAAGTACTAACTTGCAGGATAGATTGAGAAAAAAAGAA
2、PoIFN-α基因和pGAPZαA质粒的双酶切体系反应和连接反应
用NotⅠ、XhoⅠ分别对poIFN-α基因和pGAPZαA质粒双酶切,酶切反应体系分别为:
用T4 DNA连接酶对poIFN-α基因和pGAPZαA质粒的双酶切产物进行连接,16℃连接过夜。连接体系入下:
pGAPZαA双酶切产物 | 5μL |
poIFN-α双酶切产物 | 10μL |
T4 DNA连接酶 | 1μL |
10×Ligation buffer | 2μL |
DDW | 2μL |
总体系 | 20μL |
3、连接产物转化Top10F’感受态
取100μL大肠杆菌Top10F’感受态细胞于新1.5mL离心管(预冷),将连接产物全部加入于冰水混合物作用30min;冰浴结束后,将离心管移入42℃的水浴锅中,热击90s;热冲击后迅速转移到冰水混合物中,冰浴2min后加入900μL LB培养基;轻轻混匀于37℃/180rpm振荡培养1h;振荡培养结束后将菌液低速离心3min,无菌条件下弃多余上清,留约100μL上清重悬菌体沉淀;将转化产物100μL涂布于含有25μg/mL Zeocin的低盐LB固体培养基,37℃培养18h-24h。
4、重组质粒的鉴定
从转化后培养的低盐LB平板上挑取疑似阳性的白色单个菌落接种于含25μg/mLZeocin的低盐LB液体培养基中,37℃振荡培养过夜直接以菌液为模板进行鉴定反应。体系与程序为:94℃变性30s,54℃退火30s,72℃延伸30s,共运行35个循环,最后72℃延伸10min。同时以去离子水代替模板做空白对照。PCR结束后各取5μL产物在0.8%琼脂糖凝泳电泳检测。对PCR鉴定为阳性的转化菌参照质粒抽提试剂盒说明提取重组质粒pGAPZαA-poIFN-α。
如图1和2所示,在图1中泳道M为DNA Maker DL 2000,泳道poIFN-α为猪α-干扰素PCR扩增的条带;在图2中泳道M为DNA Maker DL 2000,将菌液PCR鉴定为阳性的菌株扩培提取的质粒(编号为1号质粒和2号质粒),1-4为分别为1号质粒、NotⅠ单酶切、XhoⅠ单酶切、NotⅠ和XhoⅠ双酶切的条带;泳道5-8为2号质粒、NotⅠ单酶切、XhoⅠ单酶切、NotⅠ和XhoⅠ双酶切的条带。
实施例2
重组质粒转入毕赤酵母菌表达宿主中
1、用BspHⅠ对重组质粒pGAPZαA-poIFN-α进行单酶切,酶切反应体系为:
2、X33感受态的制备
用无菌牙签挑取单菌落X33接种于10mL的YPD培养液中30℃振荡培养过夜;取部分过夜培养物按1:1000的比例接种于的新鲜YPD培养液中30℃振荡培养至菌液OD=1.3~1.5。4℃,1500g离心5分钟用30mL的无菌水重悬菌体;同样离心收集菌体用30mL的无菌水重悬菌体;同样离心收集菌体用20mL预冷的1M山梨醇重悬菌体;4℃,1500g离心5分钟用500μL预冷的1M山梨醇重悬菌体即得感受态细胞用于当天电转(置于冰上),不要冻存细胞。
3、线性化重组质粒电转感受态细胞
取80μL新制备的感受态酵母细胞与25μL线性化的重组质粒轻轻混匀。转入预冷电转杯中冰浴5分钟。设定电转化参数1500v,25μF,电阻186Ω,电击结束,立即加入1mL预冷的1M山梨醇,轻轻混匀后转入5mL的离心管中。30℃温箱中静置培养2小时。用100μL重悬菌体并铺于新鲜制备的YPDS平板(含100μg/mL的Zeocin)上将平板倒置于30℃温箱中培养3天。
4、重组转化子的高抗性筛选
将在100μg/mL抗生素抗性的YPDS平板中生长良好的菌落挑选接种到250μg/mL抗生素抗性的YPDS平板中,250μg/mL抗生素抗性的YPDS平板中生长良好的菌落继续挑选接种到500μg/mL抗生素抗性的YPDS平板中,500μg/mL抗生素抗性的YPDS平板中生长良好的菌落继续挑选接种到1000μg/mL抗生素抗性的YPDS平板中。挑选在1000μg/mL抗生素抗性的YPDS平板中生长较好的转化子在250μg/mL抗生素抗性的YPDS平板中划线纯化单克隆,以备下一步操作。
实施例3
重组毕赤酵母菌的诱导表达
将筛选的多个酵母克隆接种于5mL YPD培养液中,30℃振荡培养16h(OD约为4.0~6.0),然后按比例1:1000接种于30mLYPD培养液中,30℃振荡培养。每隔24小时取样,并补充等体积的YPD培养液,连续培养96小时,共取样四次,以14000rpm的转速离心8min,取上清,并保留沉淀,保存在-20℃。
实施例4
表达产物的SDS-PAGE凝胶电泳分析
1、相关试剂的配制
10%SDS:1g SDS溶于10mL水中,65℃水浴溶解,室温保存(电泳室抽屉)。
5×SDS-PAGE电泳缓冲液:Tris 15.1g,甘氨酸94g,加入SDS 5g,定容至1000mL。
10%过硫酸铵:称取过硫酸铵1g溶于10mL水中,分装于1.5mL离心管中,4℃保存(使用不超过一周,冰箱保存)。
1.5M Tris-HCL:18.17g Tris,PH=8.8,定容至100mL
1M Tris-HCL:12.12g Tris,PH=6.8,定容至100mL(冰箱4℃保存)
染色液:考马斯亮蓝R-250 1.5g,甲醇270mL,冰乙酸60mL,定容至600mL
30%Arc-Bis:丙烯酰胺29g,甲叉双丙烯酰胺1g,定容100mL,4℃避光保存
脱色液:冰乙酸300mL,无水乙醇100mL,双蒸水600mL。
2、SDS-PAGE凝胶的配制
3、重组毕赤酵母菌pGAPZαA-poIFN-αSDS-PAGE验证
将保存的上清加入5×Protein Loding Buffer,混匀,100℃沸水浴10min,以蛋白质标准分子量为参考,在分离胶为12%的SDS-PAGE蛋白胶上电泳,按以下步骤操作:
(1)先将样品梳移去,用双蒸水淋洗每个样品孔,然后在样品孔中加入电泳缓冲液,同时在电泳槽中也加满电泳缓冲液。处理完毕后,根据实验的需要加样电泳。
(2)通常使用稳压的方式进行电泳,电压一般为80V,30min,后调为120V,1h。待溴酚蓝带移至凝胶底部即可结束电泳(约需1-2小时)。
(3)电泳完毕后,倒去电泳缓冲液,取出夹心槽。小心地取出凝胶,放入染色液中置于水平摇床上中染色1-2小时。染色完毕后,倒去染色液,用少量水淋洗凝胶,然后置于脱色液中脱色,并轻轻晃动,脱色至蓝色背景消失为止(约需1.5-2小时,换脱色液2-3次)。此凝胶即可用于观察、分析、拍片。
如图3和4所示,图3为毕赤酵母系统重组猪α-干扰素X33-51菌株的SDS-PAGE电泳检测结果。在图3中泳道M为蛋白低分子Maker 40kD,泳道1-4是pGAPZαA-poIFN-α的X33-51菌株24h/48h/72h/96h酵母表达产物。
图4为毕赤酵母系统重组猪α-干扰素X33-29菌株的SDS-PAGE电泳检测结果。在图4中泳道M为蛋白低分子Maker 40kD,泳道5-8是pGAPZαA-poIFN-α的X33-29菌株24h/48h/72h/96h酵母表达产物。
实施例5
重组猪α干扰素生物学活性测定
PRV的半数细胞感染量(TCID50)的测定
按Reed-Muench法进行:将生长良好的BHK-21细胞用胰酶将其消化下来再用含2%灭活新生小牛血清的DMEM培养液配成悬液于96孔细胞培养板上每孔加入细胞悬液100μL,置37℃、5%CO2培养箱中培养至均匀的单层细胞。弃去培养板中的营养液,于96孔细胞培养板上再加入180μL含2%灭活新生小牛血清的DMEM培养液分别将20μL PRV病毒加入该细胞培养板装有180μL培养液的第一排孔中将混合液吹打均匀后吸取20μL混合液加入到装有180μL培养液的第二孔中更换枪头如上吹打混匀后再吸取20μL混合液加入到装有180μL培养液的第三孔中连续如此操作即可作一系列10倍稀释。每个稀释度作8个重复病毒液做6个10倍梯度稀释。细胞对照孔加入180μL含2%灭活新生小牛血清的DMEM培养液置37℃、5%CO2培养箱培养逐日观察(1~4d),直到终点。即能看到引起细胞病变的病毒最高稀释度按Reed-Muench法计算PRV的TCID50。根据下表按Reed-Muench法计算TCID50:
2、重组猪α干扰素抗病毒活性测定
具体步骤如下:
(1)铺板:弃去BHK-21细胞培养瓶中的培养液用胰酶消化收集细胞,加入含2%灭活新生小牛血清的DMEM培养液吹打均匀配成细胞悬液。然后接种于96孔细胞培养板每孔100微升37℃、5%CO2培养箱中培养过夜使细胞贴壁为单层。
(2)制备干扰素溶液:取表达上清经0.22μm的滤器过滤,接种于无任何抗生素的LB培养液中作无菌检验。检验合格后用细胞维持液作连续4倍梯度稀释。
(3)加样:取预先培养成细胞单层的96孔细胞培养板弃去营养液将不同稀释度的干扰素样品移入96孔细胞培养板每孔100微升。每个浓度作7个重复,37℃、5%CO2培养箱中培养过夜。同时设置不加病毒的空白对照和不加干扰素的阴性对照。
(4)制备病毒液:攻毒剂量100TCID50取保存的PRV用细胞维持液稀释至工作浓度。
(5)攻毒:弃去96孔细胞培养板中培养液甩干加入工作浓度的病毒液每孔100微升,37℃、5%CO2条件下培养约24小时至36小时。
(6)细胞病变判定:待病毒对照孔出现完全细胞病变时判断结果并根据细胞的病变程度按5分级制进行打分记录不同浓度时的保护性。
细胞病变的保护程度划为5等级
4:无明显的细胞病变
3:细胞病变在25%左右
2:有约50%的细胞病变
1:细胞病变在75%左右
0:有100%病变
(7)结果计算:根据Reed-Muench法计算。50%细胞病变保护的稀释度中所含的干扰素量即为1个干扰素单位。
根据下表按Reed-Muench法计算poIFN-α的效价:
上述实施例和说明书中描述的只是说明本发明的原理和最佳实施例,在不脱离本发明精神和范围的前提下,本发明还会有各种变化和改进,这些变化和改进都落入要求保护的本发明范围内。
Claims (9)
1.一种重组猪α-干扰素的制备方法,其特征在于:所述的方法通过将猪α-干扰素基因通过表达载体导入毕赤酵母菌,再通过毕赤酵母菌的诱导表达、发酵和后提取制得。
2.根据权利要求1所述的一种重组猪α-干扰素的制备方法,其特征在于:所述的制备方法包括猪α-干扰素真核表达载体的构建、重组酵母菌的诱导表达,包括以下步骤:
S1)、利用毕赤酵母密码子的偏爱性优化猪α-干扰素poIFN-α基因序列,优化后的poIFN-α序列如SEQ ID NO.1所示;
并将合成的基因构建入pGAPZαA载体中,人工合成含有目的基因的重组质粒pGAPZαA-poIFN-α;
S2)、通过毕赤酵母感受态的制备,电转重组质粒,将合成的重组质粒pGAPZαA-poIFN-α导入毕赤酵母中进行种子液的制备,以及摇瓶发酵诱导重组蛋白的表达。
3.根据权利要求2所述的一种重组猪α-干扰素的制备方法,其特征在于:所述的重组质粒pGAPZαA-poIFN-α的构建方法的步骤:
将目的基因PoIFN-α和载体pGAPZαA分别进行双酶切,酶切位点是NotⅠ、XhoⅠ,然后将酶切回收产物poIFN-α和pGAPZαA进行连接,并将连接产物导入大肠杆菌Top10F’感受态细胞中,然后利用试剂盒提取获得重组质粒pGAPZαA-PoIFN-α。
4.根据权利要求3所述的一种重组猪α-干扰素的制备方法,其特征在于:对重组质粒pGAPZαA-poIFN-α进行线性化并纯化后电击转化至毕赤酵母X33感受态细胞中。
5.根据权利要求4所述的一种重组猪α-干扰素的制备方法,其特征在于:将通过电击转化导入毕赤酵母感受态细胞的重组毕赤酵母菌液涂布在YPDS+Zeocin的低抗性平板上,并进行多次的高抗性筛选。
6.根据权利要求5所述的一种重组猪α-干扰素的制备方法,其特征在于,所述重组毕赤酵母菌的诱导表达采用如下步骤:
将筛选的重组酵母菌划线接种到YPDS+Zeocin的抗性平板上,30℃培养,挑取单菌落接种至YPD液体培养基中,30℃摇床培养16h,得到种子液;
然后将种子液按比例接种至YPD液体培养基中,30℃开始诱导表达,每隔24小时,取发酵液保存,并补充等量的培养基,保存的酵母菌即为通过表达载体导入毕赤酵母的重组猪α-干扰素,取发酵液检测重组蛋白的表达情况。
7.根据权利要求6所述的一种重组猪α-干扰素的制备方法,其特征在于:每隔24小时,取1mL发酵液保存,并补充1mL的培养基,连续培养发酵96小时。
8.根据权利要求3所述的一种重组猪α-干扰素的制备方法,其特征在于:将连接产物转化大肠杆菌Top10F’感受态细胞:
具体为:将连接产物加入大肠杆菌Top10F’感受态细胞中,轻弹两下后,再将离心管放置于冰水混合物中冰浴30min;冰浴结束后,将离心管移入42℃的水浴锅中,热击90s;热冲击后迅速转移到冰水混合物中,冰浴2min后加入900μL LB培养基;轻轻混匀于37℃/180rpm振荡培养1h;振荡培养结束后将菌液低速离心3min,无菌条件下弃多余上清,留约100μL上清重悬菌体沉淀;将转化产物100μL涂布于含有25μg/mL Zeocin的低盐LB固体培养基,37℃培养18h-24h。
9.根据权利要求4所述的一种重组猪α-干扰素的制备方法,其特征在于:线性化重组质粒电转感受态细胞具体为:
取80μL新制备的感受态酵母细胞与25μL线性化的重组质粒轻轻混匀。转入预冷电转杯中冰浴5分钟。设定电转化参数1500v,25μF,电阻186Ω,电击结束,立即加入1mL预冷的1M山梨醇,轻轻混匀后转入5mL的离心管中。30℃温箱中静置培养2小时。用100μL重悬菌体并铺于新鲜制备的YPDS平板上,将平板倒置于30℃温箱中培养3天。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210798787.5A CN116514950A (zh) | 2022-07-06 | 2022-07-06 | 一种重组猪α-干扰素的制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210798787.5A CN116514950A (zh) | 2022-07-06 | 2022-07-06 | 一种重组猪α-干扰素的制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN116514950A true CN116514950A (zh) | 2023-08-01 |
Family
ID=87394604
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210798787.5A Pending CN116514950A (zh) | 2022-07-06 | 2022-07-06 | 一种重组猪α-干扰素的制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN116514950A (zh) |
-
2022
- 2022-07-06 CN CN202210798787.5A patent/CN116514950A/zh active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN112695053A (zh) | 一种重组猫干扰素的制备方法 | |
CN102703457A (zh) | 一种抗菌肽基因的制备及表达方法 | |
CN110791508B (zh) | 密码子优化的片球菌素基因、表达载体及重组工程菌株 | |
CN102010867A (zh) | 重组中华蜜蜂王浆主蛋白AccMRJP1的酵母表达方法及产物用途 | |
CN116514950A (zh) | 一种重组猪α-干扰素的制备方法 | |
CN108795891B (zh) | 一种葡萄糖氧化酶CnGODA及其基因与应用 | |
CN101974536B (zh) | 重组人干扰素β1a基因、其表达载体和重组人干扰素β1a的制备方法 | |
CN109608535B (zh) | 一种优化的鸡α干扰素肽链及其重组表达工程菌株 | |
CN111254103B (zh) | 一种非洲猪瘟基因工程疫苗高密度发酵补料培养基及发酵工艺 | |
CN108948163A (zh) | 澳洲坚果植物防御素及其应用 | |
CN110437328B (zh) | 一种猪干扰素α突变体YNS及其制备方法和应用 | |
CN110698554B (zh) | 东亚飞蝗fkbp52蛋白及其编码基因和应用 | |
CN109517775B (zh) | 大黄鱼IFNc基因大肠杆菌表达产物的制备方法与应用 | |
CN109251867B (zh) | 一种酸性蛋白酶高产菌株及其应用 | |
CN107653254B (zh) | 一种猪繁殖与呼吸综合症病毒重组orf5基因及其制备方法 | |
CN108611357A (zh) | 一种重组表达质粒、转化子及其应用 | |
CN109161489B (zh) | 一种高产酸性蛋白酶的黑曲霉菌株 | |
CN106319001B (zh) | 一种重组干扰素γ的产业化制备方法与应用 | |
CN110343164A (zh) | 一种高活性7位点突变的猪干扰素α突变体及其制备方法和应用 | |
CN102533841A (zh) | 一种提高Bt杀虫蛋白在汉逊酵母中表达量的方法 | |
CN103937828A (zh) | 一种猪干扰素α1与胸腺肽α1融合蛋白的制备技术 | |
CN110791509B (zh) | 片球菌素优化表达序列、表达载体及其制作方法和菌株 | |
CN114921354B (zh) | 一种产虫草素及其衍生物3’-脱氧肌苷的工程菌株及其制备方法和应用 | |
CN115947815B (zh) | 一种重组抗菌肽pmap-37及其制备方法和应用 | |
CN117304344B (zh) | 一种融合蛋白、表达该融合蛋白的重组菌株及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |